Jawad H Butt1, Jonas B Olesen2, Eva Havers-Borgersen3, Anna Gundlund2, Charlotte Andersson2, Gunnar H Gislason4, Christian Torp-Pedersen5, Lars Køber3, Emil L Fosbøl3. 1. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: jawad_butt91@hotmail.com. 2. Department of Cardiology, Herlev and Gentofte University Hospital, Hellerup, Denmark. 3. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 4. Department of Cardiology, Herlev and Gentofte University Hospital, Hellerup, Denmark; The Danish Heart Foundation, Copenhagen, Denmark; The National Institute of Public Health, University of Southern Denmark, Odense, Denmark. 5. Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
Abstract
BACKGROUND: The long-term risk of thromboembolism in patients developing new-onset post-operative atrial fibrillation (POAF) following noncardiac surgery is unknown, and data on stroke prophylaxis in this setting are lacking. OBJECTIVES: The purpose of this study was to assess the long-term risk of thromboembolism in patients developing new-onset POAF following noncardiac surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). METHODS: Using Danish nationwide registries, the authors identified all patients who developed POAF following noncardiac surgery from 1996 to 2015. These were matched by age, sex, heart failure, hypertension, diabetes, previous thromboembolism, ischemic heart disease, and year of diagnosis to patients with nonsurgical NVAF in a 1:4 ratio. Comparative long-term risk of thromboembolism was examined by multivariable Cox regression models. RESULTS: In patients undergoing noncardiac surgery, 6,048 (0.4%) developed POAF during hospitalization, with the highest incidences following thoracic/pulmonary, vascular, and abdominal surgery. A total of 3,830 patients with POAF were matched with 15,320 patients with NVAF. Oral anticoagulation therapy was initiated within 30 days post-discharge in 24.3% and 41.3% of these patients, respectively (p value <0.001). The long-term risk of thromboembolism was similar in patients with POAF and NVAF (31.7 events vs. 29.9 events per 1,000 person years; hazard ratio [HR]: 0.95; 95% confidence interval [CI]: 0.85 to 1.07). Anticoagulation therapy during follow-up was associated with a comparably lowered risk of thromboembolic events in patients with POAF (HR: 0.52; 95% CI: 0.40 to 0.67) as well as NVAF (HR: 0.56; 95% CI: 0.51 to 0.62) compared with no anticoagulation therapy. CONCLUSIONS: New-onset POAF following noncardiac surgery was associated with a long-term risk of thromboembolism similar to NVAF.
BACKGROUND: The long-term risk of thromboembolism in patients developing new-onset post-operative atrial fibrillation (POAF) following noncardiac surgery is unknown, and data on stroke prophylaxis in this setting are lacking. OBJECTIVES: The purpose of this study was to assess the long-term risk of thromboembolism in patients developing new-onset POAF following noncardiac surgery relative to patients with nonsurgical, nonvalvular atrial fibrillation (NVAF). METHODS: Using Danish nationwide registries, the authors identified all patients who developed POAF following noncardiac surgery from 1996 to 2015. These were matched by age, sex, heart failure, hypertension, diabetes, previous thromboembolism, ischemic heart disease, and year of diagnosis to patients with nonsurgical NVAF in a 1:4 ratio. Comparative long-term risk of thromboembolism was examined by multivariable Cox regression models. RESULTS: In patients undergoing noncardiac surgery, 6,048 (0.4%) developed POAF during hospitalization, with the highest incidences following thoracic/pulmonary, vascular, and abdominal surgery. A total of 3,830 patients with POAF were matched with 15,320 patients with NVAF. Oral anticoagulation therapy was initiated within 30 days post-discharge in 24.3% and 41.3% of these patients, respectively (p value <0.001). The long-term risk of thromboembolism was similar in patients with POAF and NVAF (31.7 events vs. 29.9 events per 1,000 person years; hazard ratio [HR]: 0.95; 95% confidence interval [CI]: 0.85 to 1.07). Anticoagulation therapy during follow-up was associated with a comparably lowered risk of thromboembolic events in patients with POAF (HR: 0.52; 95% CI: 0.40 to 0.67) as well as NVAF (HR: 0.56; 95% CI: 0.51 to 0.62) compared with no anticoagulation therapy. CONCLUSIONS: New-onset POAF following noncardiac surgery was associated with a long-term risk of thromboembolism similar to NVAF.
Authors: Heidi Oi-Yee Li; Heather A Smith; Olivier Brandts-Longtin; Donna E Maziak; Sebastien Gilbert; Paul Villeneuve; Sudhir Sundaresan; Andrew J E Seely Journal: Gen Thorac Cardiovasc Surg Date: 2021-01-05
Authors: Wojciech Szczeklik; Yannick LeManach; Jakub Fronczek; Kamil Polok; David Conen; Finlay A McAlister; Sadeesh Srinathan; Pablo Alonso-Coello; Bruce Biccard; Emmanuelle Duceppe; Diane Heels-Ansdell; Jacek Górka; Shirley Pettit; Pavel S Roshanov; P J Devereaux Journal: CMAJ Date: 2020-12-07 Impact factor: 8.262
Authors: Jawad Haider Butt; Jonas Bjerring Olesen; Anna Gundlund; Thomas Kümler; Peter Skov Olsen; Eva Havers-Borgersen; David Thein Aagaard; Gunnar Hilmar Gislason; Christian Torp-Pedersen; Lars Køber; Emil Loldrup Fosbøl Journal: JAMA Cardiol Date: 2019-11-01 Impact factor: 14.676
Authors: David Amar; Hao Zhang; Mina K Chung; Kay See Tan; Dawn Desiderio; Bernard J Park; Alessia Pedoto; Nancy Roistacher; James M Isbell; Daniela Molena; Ginger L Milne; Bryan F Meyers; Gregory W Fischer; Valerie W Rusch; David R Jones Journal: Anesthesiology Date: 2022-06-01 Impact factor: 7.892
Authors: Konstantinos C Siontis; Bernard J Gersh; Susan A Weston; Ruoxiang Jiang; Véronique L Roger; Peter A Noseworthy; Alanna M Chamberlain Journal: Ann Intern Med Date: 2022-07-26 Impact factor: 51.598
Authors: Michael G Fradley; Kerry Ellenberg; Mohammed Alomar; Justin Swanson; Anant Kharod; Anh Thy H Nguyen; Sara Khodor; Shreya Mishra; Linh M Duong; Nirav Shah; Merna Armanious; Isaac B Rhea; Matthew B Schabath; Kevin E Kip Journal: JACC CardioOncol Date: 2020-12-15
Authors: Jason D Matos; Susan McIlvaine; Maria Grau-Sepulveda; Oliver K Jawitz; J Matthew Brennan; Kamal R Khabbaz; Frank W Sellke; Robert Yeh; Peter Zimetbaum Journal: J Thorac Cardiovasc Surg Date: 2020-02-19 Impact factor: 6.439